Suzanne Sherman
Ophthalmology · New York, NYNPI 1770923732
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $824 of the $1,278 with a category attached, or 64.5%. 12 manufacturers reported payments, led by Amgen at 30.5% of the total. Reporting peaked in 2019 at $522 and has fallen 52.9% since, to $246 in 2025. That places this record below the midpoint for ophthalmology clinicians in NY, where the typical reported total is $1,047.
Across 24 payments — averaging $53.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$390
- Alcon$286
- Coopervision Inc.$159
- Johnson & Johnson Vision Care, Inc.$159
- Dompe US, Inc.$113
- Novartis$30
- plus $142 from 6 others
What the payments were for
- Consulting fees$30023%
- Speaking & faculty fees$15012%
- Travel & lodging$40%
- Food & beverage$82464%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 3 | $390 |
| Alcon | 5 | $286 |
| Coopervision Inc. | 4 | $159 |
| Johnson & Johnson Vision Care, Inc. | 4 | $159 |
| Dompe US, Inc. | 1 | $113 |
| Novartis | 1 | $30 |
| Bausch & Lomb Americas Inc. | 1 | $28 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $24 |
| Shire North American Group Inc | 1 | $24 |
| Oyster Point Pharma, Inc. | 1 | $22 |
| Kala Pharmaceuticals, Inc. | 1 | $22 |
| Eyevance Pharmaceuticals LLC | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$390
- AcrySof IQ VIVITY$127
- Oxervate$113
How this compares
$1,278 in reported general payments places this provider in the 50th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 46 | $29,996 |
| Latanoprost | 45 | $369 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 34 | $320 |
| MoxifloxacinMoxifloxacin Hcl | 12 | $260 |
| ErythromycinErythromycin Base | 18 | $135 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in New York
- Nathan RadcliffeNew York$2.1M
- Richard SpaideNew York$1.7M
- Joshua YoungNew York$814K
- Joseph PanarelliNew York$541K
- Eric RosenbergNew York$434K
- Michael CooneyNew York$398K
- David GuyerNew York$322K
- Ashley BrissetteNew York$315K
- Jason SlakterNew York$272K
- David ChuNew York$234K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.